MX9805253A - Vitronectin receptor antagonists. - Google Patents

Vitronectin receptor antagonists.

Info

Publication number
MX9805253A
MX9805253A MX9805253A MX9805253A MX9805253A MX 9805253 A MX9805253 A MX 9805253A MX 9805253 A MX9805253 A MX 9805253A MX 9805253 A MX9805253 A MX 9805253A MX 9805253 A MX9805253 A MX 9805253A
Authority
MX
Mexico
Prior art keywords
receptor antagonists
vitronectin receptor
vitronectin
osteoporosis
compounds
Prior art date
Application number
MX9805253A
Other languages
Spanish (es)
Inventor
Fadia E Ali
William E Bondinell
Richard M Keenan
Thomas Wen Fu Ku
William H Miller
James Samanen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX9805253A publication Critical patent/MX9805253A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis.
MX9805253A 1995-12-29 1998-06-26 Vitronectin receptor antagonists. MX9805253A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US953295P 1995-12-29 1995-12-29

Publications (1)

Publication Number Publication Date
MX9805253A true MX9805253A (en) 1998-10-31

Family

ID=21738237

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9805253A MX9805253A (en) 1995-12-29 1998-06-26 Vitronectin receptor antagonists.

Country Status (16)

Country Link
EP (1) EP0895475A4 (en)
JP (1) JP2000502708A (en)
KR (1) KR19990076876A (en)
CN (1) CN1209060A (en)
AU (1) AU1353897A (en)
BR (1) BR9612378A (en)
CA (1) CA2241724A1 (en)
CZ (1) CZ203798A3 (en)
HU (1) HUP9901116A2 (en)
IL (1) IL125034A0 (en)
MX (1) MX9805253A (en)
NO (1) NO983002L (en)
PL (1) PL327919A1 (en)
TR (1) TR199801255T2 (en)
WO (1) WO1997024122A1 (en)
ZA (1) ZA9610855B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10504825A (en) * 1994-08-22 1998-05-12 スミスクライン・ビーチャム・コーポレイション Bicyclic compound
WO1997026250A1 (en) * 1996-01-16 1997-07-24 Merck & Co., Inc. Integrin receptor antagonists
JP2000508319A (en) * 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αvβ3 antagonist
US20030125317A1 (en) 1996-10-02 2003-07-03 Smithkline Beecham Corporation Vitronectin receptor antagonists
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
DE19653645A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
US6482821B2 (en) 1996-12-20 2002-11-19 Hoechst Aktiengellschaft Vitronectin receptor antagonists, their preparation and their use
US6218387B1 (en) 1996-12-20 2001-04-17 Hoechst Aktiengesellschaft Vitronectin receptor anatagonists, their preparation and their use
EP1000031A4 (en) * 1997-07-25 2001-08-16 Smithkline Beecham Corp Vitronectin receptor antagonist
JP2002508323A (en) * 1997-12-17 2002-03-19 メルク エンド カムパニー インコーポレーテッド Integrin receptor antagonist
CA2323208A1 (en) * 1998-03-10 1999-09-16 James M. Samanen Vitronectin receptor antagonists
ATE253569T1 (en) * 1998-04-01 2003-11-15 Janssen Pharmaceutica Nv PDE-IV INHIBITING PYRIDINE DERIVATIVES
GB9812088D0 (en) * 1998-06-05 1998-08-05 Celltech Therapeutics Ltd Chemical compounds
SE9803518D0 (en) * 1998-10-15 1998-10-15 Astra Pharma Prod Novel compounds
EP1150965A4 (en) 1999-02-03 2002-05-15 Merck & Co Inc Benzazepine derivatives as alpha-v integrin receptor antagonists
US6723711B2 (en) * 1999-05-07 2004-04-20 Texas Biotechnology Corporation Propanoic acid derivatives that inhibit the binding of integrins to their receptors
MXPA02000722A (en) 1999-07-21 2002-07-22 Wyeth Corp Bicyclic antagonists selective for the alpha;v.
EG24179A (en) * 1999-09-07 2008-09-28 Smithkline Beecham Corp Vitronectin receptor antagonists
DE10028575A1 (en) 2000-06-14 2002-03-14 Basf Ag integrin
FR2800067B1 (en) * 1999-10-21 2004-12-17 Rhodia Chimie Sa INTERMEDIATES FOR THE MANUFACTURE OF A BENZOFURANE OR NITROGEN BENZOTHIOPHENE DERIVATIVE IN POSITION 5 AND THEIR USES
FR2820743B1 (en) * 2001-02-09 2005-02-25 Pf Medicament SYNTHESIS METHOD AND INTERMEDIARIES FOR THE PREPARATION OF PYRIDIN-2-YL-METHYLAMINE DERIVATIVES
RU2316337C2 (en) 2001-04-24 2008-02-10 Мерк Патент Гмбх Combined therapy by using antiangiogenic agents and tnf-alpha
AU2004283751B2 (en) * 2003-10-24 2011-05-19 Exelixis, Inc. p70S6 kinase modulators and method of use
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
WO2006041046A1 (en) * 2004-10-13 2006-04-20 Sankyo Company, Limited Pyridine derivative
CN101228129A (en) 2005-04-20 2008-07-23 詹森药业有限公司 Fluorinated pyridine N-oxide thrombin modulators and process for N-oxidation of nitrogen containing heteroaryls
ES2521679T3 (en) 2006-01-18 2014-11-13 Merck Patent Gmbh Specific therapy using integrin ligands for cancer treatment
AR060901A1 (en) * 2006-05-12 2008-07-23 Jerini Ag HETEROCICLICAL COMPOUNDS FOR THE INHIBITION OF INTEGRINS AND USE OF THESE
EP2101805B1 (en) 2007-01-18 2012-11-07 Merck Patent GmbH Integrin ligands for use in treating cancer
US9345739B2 (en) 2007-11-08 2016-05-24 The General Hospital Corporation Methods and compositions for the treatment of proteinuric diseases
MX2011012345A (en) 2009-05-22 2012-01-31 Exelixis Inc Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases.
CA2763275A1 (en) 2009-05-25 2010-12-02 Merck Patent Gmbh Continuous administration of integrin ligands for treating cancer
WO2011082967A1 (en) * 2009-12-17 2011-07-14 Basf Se Method for producing higher ethanolamines
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
MX2016015467A (en) 2014-05-30 2017-03-23 Pfizer Carbonitrile derivatives as selective androgen receptor modulators.
CA3026226A1 (en) 2016-06-13 2017-12-21 Glaxosmithkline Intellectual Property Development Limited Substituted pyridines as inhibitors of dnmt1
US11046685B2 (en) 2017-02-28 2021-06-29 Morphic Therapeutic, Inc. Inhibitors of (α-v)(β-6) integrin
AU2018229275B2 (en) 2017-02-28 2021-12-23 Morphic Therapeutic, Inc. Inhibitors of (alpha-v)(beta-6) integrin
US20200071322A1 (en) 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiting (alpha-v)(beta-6) integrin
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627754A (en) * 1970-05-13 1971-12-14 Hoffmann La Roche Process for preparing 7-lower alkanoyl benzodiazepines utilizing ceric salts
CA2112360A1 (en) * 1991-06-28 1993-12-23 William Edward Bondinell Bicyclic fibrinogen antagonists
CN1041921C (en) * 1992-12-21 1999-02-03 史密丝克莱恩比彻姆公司 Bicyclic fibrinogen antagonists
JPH10504807A (en) * 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション Vitronectin receptor antagonist
EP0906103A1 (en) * 1995-12-29 1999-04-07 Smithkline Beecham Corporation Vitronectin receptor antagonists
ZA9610853B (en) * 1995-12-29 1998-04-06 Smithkline Beecham Corp Processes and intermediates for preparing pharmaceuticals.

Also Published As

Publication number Publication date
ZA9610855B (en) 1997-11-24
IL125034A0 (en) 1999-01-26
HUP9901116A2 (en) 2000-03-28
EP0895475A1 (en) 1999-02-10
CN1209060A (en) 1999-02-24
JP2000502708A (en) 2000-03-07
CA2241724A1 (en) 1997-07-10
KR19990076876A (en) 1999-10-25
WO1997024122A1 (en) 1997-07-10
PL327919A1 (en) 1999-01-04
AU1353897A (en) 1997-07-28
BR9612378A (en) 1999-07-13
NO983002D0 (en) 1998-06-26
TR199801255T2 (en) 1998-10-21
NO983002L (en) 1998-08-26
EP0895475A4 (en) 2000-08-23
CZ203798A3 (en) 1998-12-16

Similar Documents

Publication Publication Date Title
MX9805253A (en) Vitronectin receptor antagonists.
TR199801253T2 (en) Vitronectin receptor antagonists.
MX9700041A (en) Vitronectin receptor antagonists.
GB9514473D0 (en) Chemical compounds
BG103548A (en) Vitronectine receptor antagonists
EP0760658A4 (en) Compounds for inhibiting osteoclast-mediated bone resorption
YU76100A (en) Pyrolo(2,3d) pyrimidine compositions and their use
YU20600A (en) This invention relates to the use of 5-ht3 receptor
MY113806A (en) Antiparasitic marcfortines and paraherquamides
NZ307625A (en) 1-benzoyl-2-(indolyl-3-alkyl)-piperazine derivatives as neurokinin receptor antagonists
AP9801312A0 (en) 4-aminopyrrole (3,2-d) pyrimidines as neuropeptide y receptor anatagonist.
BG103485A (en) Ketobanzamides as calpain inhibitors
AU3642795A (en) Endothelin receptor antagonists for the treatment of emesis
MX9801890A (en) Novel human nk3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them.
NO975975L (en) Vitronectin receptor antagonists, preparation and use thereof
AP2000001766A0 (en) Vitronectin receptor anatagonists.
AP2000001898A0 (en) Vitronectin receptor antagonists
NO20001514L (en) Vitronectin receptor antagonist
PL346981A1 (en) 2-methyl-thieno-benzodiazepine formulation
ZA961364B (en) 1-Aryl-2-acylamino-ethane compounds
BG104038A (en) Use of specific antagonist of 5ht2 receptors for preparing medicines useful for treating sleep-disordered breathing
EP0714295A4 (en)
AU3745795A (en) Use of CCK-B receptor antagonists for the treatment of sleepdisorders
CA2311423A1 (en) Method for treating hyperlipidemia
AP1534A (en) Vitronectin receptor antagonists.